# 1. Financial Performance ## A. Key Figures * Revenue from Operations: **₹221.7 Cr** Q3 FY'26 (+92% YoY, +17% QoQ) * EBITDA: ₹100.8 Cr (+240% YoY), margin >45% * PAT: **₹66.7 Cr** (+400% YoY), margin 30% * **Gross Profit:** **₹5 Cr**, margin 89% ## B. Revenue Growth * **Strong Momentum Across Segments:** Robust top-line growth driven by expanding demand in both Ayurvedic Healthcare Services and Products, with increasing patient trust amplifying traction. * **Strategic Seasonal Balancing:** Evidence of proactive quarterly smoothing, with **~20% sequential sales growth** in Q4 FY'25, indicating successful efforts to strengthen seasonally weaker periods. ## C. Profit Margins * **Exceptional Margin Expansion:** Sustained high profitability with EBITDA margin above 45% and stable 30% PAT margin, achieved despite ongoing expansion investments. * **Efficiency-Led Leverage:** Margin evolution from 6% to 30% over four years driven by **repeat customers** and **word-of-mouth**, not ad spend, highlighting strong brand loyalty and operating leverage. --- # 2. Revenue & Segment Mix ## A. Key Figures * **Revenue:** **₹215 Cr** medicine sales · **₹136 Cr** hospital services · **₹118 Cr** government services (Total: **₹469 Cr**, Mar FY25) * **Segment Mix:** **54%** healthcare · **46%** medicine sales * **Government Revenue:** Reduced to **₹8 Cr** (current quarter) from **₹118 Cr** (FY24–25) * **Insurance Revenue:** Accounts for **less than 25%** of total business ## B. Product vs Services * **Product Outperformance:** Product sales surpassed services this quarter due to **new OTC launches** and a seasonally weak prior quarter for hospitals, despite **strong double-digit growth** in both segments. * **Stable Core Mix:** Revenue distribution across government, private, and medicine segments remains consistent over recent fiscal years, excluding recent government pullback. ## C. Private vs Government * **Strategic De-risking:** Deliberate reduction in government business due to **payment delays** and **low margins**, with pivot toward higher-quality private and insurance-linked revenue. * **Minimal Government Exposure:** Government-related revenue now represents only **3%** of total revenue, reflecting successful de-risking. ## D. Insurance Contribution * **Structural Tailwind:** Regulatory shift enabling **reimbursement for daycare treatments post-hospitalization** has unlocked new revenue streams and improved patient affordability. * **Growing Insurance Adoption:** Full insurance reimbursement for Ayurvedic treatments like Panchkarma is now feasible, removing a key cost barrier and signaling **rising mainstream acceptance**. * **Untapped Upside:** Health insurance currently contributes **less than 25%** of revenue, indicating significant runway for expansion as payer coverage deepens. --- # 3. Bed Capacity & Utilization ## A. Key Figures * **Operational Beds:** **2,290** (Q3 FY’26) · **1,325 occupied** (58% occupancy) * **Total Beds Under Development:** **2,700–2,800** * **Long-Term Bed Target:** **7,000–10,000** over 3–5 years ## B. Operational Beds * **Capacity Management:** Selective bed activation—**560 beds held back**—to control costs during seasonally weak demand, particularly in Q3 (Diwali/winter). * **Leadership Position:** Company asserts status as **India’s largest clinic and hospital chain**, underpinned by scale and strategic bed deployment. * **Growth Constraints:** Operational bed additions limited to **60 beds** from Q1 to Q2 due to seasonality, weighing on near-term utilization. ## C. Occupancy Rate * **Utilization Uptick:** Occupancy improved to **58%** from 57% in prior quarters, despite being the industry’s weakest seasonal period. * **Targeted Expansion:** Management targets **70%-80% sustained occupancy** by year-end, with new beds activated only as demand materializes. ## D. Expansion Pipeline * **Hub-and-Spoke Momentum:** Ayurvedic **hub and spoke model** is scaling successfully, forming the backbone of national expansion. * **Super-Specialty Push:** Strategic shift into urban healthcare via **5–10 company-owned super-specialty hospitals**, with franchise model **paused** to protect margins. * **Wellness-Led Growth:** **Wellness patients surged to 15%** this quarter (from 5%), driving new **VVIP hospitals** and **premium wellness centers** in partnership with a top-tier brand. * **Product-Bed Synergy:** Growth strategy hinges on **parallel scaling of beds and bed-linked products** (e.g., knee/back/heart packages) to drive patient inflow and utilization. --- # 4. Product Launch & OTC Growth ## A. Key Figures * **Monthly Sales:** **₹10 Cr** for Pet Yakrit Pleeha Shuddhi Kit * **Distribution Reach:** **2,000–2,500 medical stores** across **11 states** for Nutritoz ## B. New Product Rollout * **Sequential Launch Strategy:** New product rollouts are gated on achieving **INR5 crore monthly sales** from prior launches, starting with NutriRoz this month. * **Preventive Health Focus:** All OTC products are preventive, targeting root causes of disease—exemplified by Pet Yakrit Pleeha Shuddhi Kit—aligning with Ayurveda’s core principle of *Swasthasya Swasthya Rakshanam*. * **Scientific Backing & Innovation:** Heavy R&D investment supported by **over 180 published papers**, with formulations like **Nutrition Roz** (33 herbs) targeting widespread deficiencies (e.g., Vitamin D in **80% of Delhi-NCR population**). * **Vertical Integration Plan:** Manufacturing to be brought in-house this year to boost **margins and quality control**, with options under evaluation for factory setup or acquisition. ## C. Distribution Reach * **Mass Market Push:** OTC expansion driven by affordability, daily consumption model (e.g., **two spoons of Nutritoz**), and regional language translation to enable pan-India inclusivity. * **Multi-Channel Availability:** Products launched via **social media, online platforms, and OTC**, with plans to scale through **2,000+ medical stores** and a new **Health Card loyalty program** offering **1 point per ₹1 spent** (redeemable for treatments). ## D. Clinical Validation * **Clinical Rigor:** All OTC products undergo clinical trials pre-launch—Pet Yakrit Pleeha Shuddhi Kit already validated—supporting scientific credibility despite **no IP protection against replication** of Ayurvedic formulations. --- # 5. Partnerships & Distribution ## A. Key Figures * Chandan Diagnostics Revenue: INR 10 Cr annualized (projected INR 10–15 Cr) * **Testing Volume:** **3 lakh tests/day** (up from 2 lakh in 7 days), targeting **5 lakh tests/day** * **Network Size:** **34 operational centers**, expanding to **64 within 6 months** * Entero Distribution Reach: 1.25 lakh stores, enabling access to ~10% of 9 lakh medical stores in India * Capex Investment by Partner: **≥INR 3.5 Cr** (6 new Fibroscan machines) fully borne by Chandan ## B. Diagnostic Network * **Zero-Cost Scaling:** Chandan partnership drives rapid diagnostic volume growth with **no capex, operational burden, or investment** on the company’s part. * **Revenue Model Efficiency:** Monetization via **percentage share of collections**, supported by joint patient incentives (e.g., **dual-branded discount card**) enhancing retention. * **Accelerated Expansion:** Diagnostic footprint set to nearly double within six months, with full integration across all Chandan centers planned. ## C. B2B Distribution & Strategic Positioning * **OTC Market Leap:** Entero partnership enables immediate reach to **1 lakh stores in 15 days**, unlocking scalable access to India’s vast pharmacy network. * **Asset-Light Discipline:** Strategic avoidance of retail capex in favor of **medicine sales and R&D focus** strengthens ROCE and model scalability. * **Integrated Ecosystem:** Fully internalized value chain—from **in-house pharma, diagnostics, clinics, and hospitals**—creates a **blue ocean model** with no direct competition. * **Brand Building for Global Ayurveda:** Marketing via **Masterchef and Laughter Chef** appearances aims to elevate brand visibility and position India as a leader in preventive wellness. --- # 6. Patient & Volume Metrics ## A. Key Figures * OPD & COD Video Consultations: 4.34 lakh patients (+247% YoY) * **IPD Patients:** +84% YoY · **Day Care Patients:** +139% YoY · **Video Consultations:** +214% YoY * **New Admissions:** **11,313** (latest quarter) vs. 9,600 and 8,600 in prior quarters, totaling **29,000** in nine months * **Medicine Takers:** **156,000** (current quarter) up from 140,000 and 124,000 in previous quarters * **VOPD Growth:** **41,000** (Q1) → **56,000** (Q2) → **61,000** (Q3), showing sequential expansion ## B. New Admissions * **Explosive Volume Growth:** All patient categories — IPD, day care, and video consultations — registered strong double-digit to triple-digit growth, reflecting accelerating demand and operational scaling. * **High Patient Throughput:** Admissions have more than quadrupled over three years, with recent quarters showing upward momentum despite seasonal headwinds. * **Monetization Synergy:** Patient engagement is strategically linked to product sales, creating a self-reinforcing ecosystem that enhances lifetime value. * **Growth Drivers:** Free initial testing and cashback on follow-up diagnostics have boosted footfall even in seasonally weak periods. ## C. Video Consultations * **Sustained VOPD Expansion:** Video consultations show consistent quarterly growth, now forming a material channel for patient acquisition and care delivery across geographies. * **Global Reach & Localization:** VOPD services are active in India and internationally, with upcoming regional language content (Bengali, Gujarati, Marathi) to broaden penetration beyond North India. * **Digital Engagement Upgrade:** A new gamified patient engagement platform launching in 2–3 months aims to deepen interaction and retention. ## D. Patient Retention * **Preventive Care Model:** Retention is driven by periodic Panchakarma treatments every six months, not repeat curative episodes, aligning with long-term wellness education. * **Self-Management Focus:** The business model emphasizes training patients to self-manage, reducing dependency on repeated interventions and supporting scalable care delivery. --- # 7. Pricing & Regulatory Risks ## A. Key Figures * **Government Dues Recovered:** **₹20–21 Cr** in recent months * **Product Price Adjustment:** **INR 960** reduced to **INR 900** post-GST cut, with full benefit passed to consumers ## B. Margin Pressure * **Pricing Discipline Maintained:** Company upheld Ayurvedic pricing model despite distributor margin expectations, choosing not to raise prices and fully passing GST reduction benefits to consumers. * **Preventive Care Opportunity:** Significant market potential identified in pre-diabetic and pre-hypertensive populations, who are psychologically predisposed to future chronic conditions. * **Seasonal Headwinds Expected:** Healthcare demand typically weakens from November to December due to festivals, weddings, and weather-related factors. ## C. Government Payments * **Payment Uncertainty Persists:** Recovery of ₹20–21 Cr achieved, but expansion of government business remains contingent on timely payments and resolution of systemic delays. * **Reimbursement Policy Advance:** Health insurers now clearly cover day-care treatments post short hospital stays (1–2 days), enhancing access to follow-up care. ## D. Policy Dependence * **Teleconsultation Backed by Policy:** AYUSH portal enables and promotes nationwide teleconsultations, providing regulatory validation for digital Ayurvedic care. * **Ayushman Bharat Inclusion Pending:** Ongoing talks with government for Ayurveda’s inclusion in Ayushman Yojana; positive signals but no concrete outcome to date. * **Wellness as National Imperative:** Speaker emphasizes disease prevention through health education, linking public health to economic productivity amid rising lifestyle diseases from poor diet. --- # 8. Guidance & Outlook ## A. Key Figures * **Revenue (9M FY'26):** **₹586 Cr** (vs. prior ₹750 Cr full-year expectation) * **OTC Revenue Target:** **₹500 Cr** over two financial years * **Annual Profit Guidance:** **₹225–250 Cr** (current year, all free cash) * **Long-Term Profit Target:** **₹1,000 Cr** over 3–4 years ## B. Revenue & Growth Outlook * **No Formal FY'26 Guidance:** Management refrains from revising guidance, emphasizing **patient care and valuation** over short-term numbers despite 9-month revenue trajectory. * **Confident Medium-Term Trajectory:** OTC revenue target of ₹500 Cr over two years deemed **easily attainable**; sustained **quarter-on-quarter growth** expected as strategic imperative. * **Performance Momentum:** Current quarter expected to show **further improvement** over prior quarter, supported by structural shifts in team focus and product mix. ## C. Profitability & Capital Allocation * **Profitability Scaling:** Management affirms strong current-year profitability with **₹225–250 Cr free cash profit**, targeting ₹1,000 Cr over 3–4 years. * **Self-Funded Expansion:** No reliance on external capital; **sufficient internal funds** available for growth, with dedicated allocation for **strategic acquisitions or tie-ups**. ## D. International Expansion & Strategic Vision * **Global Footprint Accelerating:** Two day care centers operational in UAE, four under construction in Dubai, with entry into **Kazakhstan and Nepal** and planning for US and other markets underway. * **Systematic Global Scaling:** Focus on proving a **profitable operating model** before deciding on franchise vs. independent expansion; **Salesforce and Oracle** implementations support international readiness. * **Synergy with Domestic Growth:** International centers positioned as feeders for Indian hospitals, leveraging **government support for Ayurveda** and rising global medical tourism. * **Pure-Play Ayurveda Leadership:** Strategic focus remains on **core verticals**—Ayurvedic products, services, diagnostics, and international—with ambition to become **#1 in India, then Asia, then globally**.